Although baseline γH2AX in the biopsy from patient #3 was not evaluable due to inadequate viable tumor cell content, baseline γH2AX in the 6 evaluable cases was < 4.0% (range, 0.3–2.5% NAP), consistent with previous case series that were not selected for BRCA1/2 defects [29]. This evidence concerns the gene BRCA1 and neoplasm.